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Abstract 
Vertebrates utilize two forms of immunity to combat pathogens. limate immunity is 
considered the first line of defense that utilizes immediate action and three barriers. Innate 
immunity responses t)^ically occur within minutes of pathogen exposure resulting in cellular 
receptor activation and acute pro-inflammatory cytokine release. Inflammatory macrophages 
engage bacterial endotoxins, including Gram-negative lipopolysaccharide (LPS) and Gram-
positive lipoteichoic acid (LTA). And respond by releasing tumor necrosis factor-a (TNF-a). 
While beneficial for neutralizing acute pathogen exposure, prolonged TNF-a release results in 
chronic inflammation and tissue damage. In the present study, we examined two methylated 
derivatives of a citric acid cycle intermediate, ñmiarate, as potential mediators of endotoxin-
induced TNF-a release. We determined that 10|iM dimethyl fumarate (DMF) significantly 
inhibited LPS-mediated soluble TNF-a released from the mouse monocyte cell line RAW 264.7, 
with no effect on cell viability or reactive oxygen species (ROS) generation. Monomethyl 
fumarate (MMF) and DMF showed minimal effects on cell viability or ROS generation. We 
found that DMF at lO^iM is anti-inflammatory with minimal monocyte cytotoxicity. The cellular 
mechanism of DMF action remains unknown. 
Introduction 
Vertebrates utilize two forms of immunity: imiate and adaptive. Innate immunity is 
considered the first line of defense that utilizes immediate action and three barriers. Physical 
bamers include the skin and mucous membrane, chemical barriers include stomach acid and 
antimicrobial properties of specialized soluble molecules, and cellular barriers include cellular 
receptors that detect microbial products (Kindt, 2007). Innate immunity responses typically 
occur within minutes of pathogen invasion. And generally, a pathogen evading the innate 
immune response triggers the adaptive immune response (Kindt, 2007). Adaptive immunity 
arises from immune B and T cells that detect and respond to a pathogen. Adaptive immunity is 
the basis for immunological memoiy, whereby pathogen exposure triggers a cell-mediated 
immune response that can escalate upon future exposures (Kindt, 2007). Pathogen recognition 
stimulates T cell diversification and B cell antibody production to orchestrate the immunological 
defense. 
Inflammation is an evolutionary conserved multicellular organismal response (Akira et 
ai, 2006). An acute inflammatory response is initiated during the early stages of infection that 
involves leukocytes, such as neutrophils and monocytes, which mobilize to contain the triggering 
event (Kindt, 2007). Vasodilation and vascular permeability increases are hallmarks of the 
inflammatory response, which allow leukocytes to undergo diapedesis, phagocytize invading 
pathogens, and synthesize and release soluble chemical mediators identified as chemokines and 
cytokines (such as tumor necrosis factor-a, TNF-a). A chronic inflammatory response arises 
when residential immune cells engage in prolonged pro-inflammatory cytokine secretion 
resulting in altered cellular phenotypes and host tissue remodeling (Kindt, 2007; Hoebe et al., 
2004). 
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Immune responses utilize energy and intermediates from metabolic pathways, which 
include glycolysis, citric acid cycle, elecfron transport and oxidative phosphorylation. Glycolysis 
occurs in the cytosol and converts glucose to pyruvate (Berg et ai, 2007; Garrett et ai, 2010). 
Pyruvate is transported into the mitochondria where it is converted to acetyl-CoA and oxidized to 
CO2 in the citric acid cycle. Oxidation liberates electrons that are delivered by NADH and 
FADH2 to the structured chain of proteins and coenzymes known as the elecfron transport chain. 
Trans-membrane fransport of electrons creates a proton gradient across the mitochondrial 
membrane, which drives ATP production through oxidative phosphorylation. ATP is produced in 
limited quantities via glycolysis and citric acid cycle with oxidative phosphorylation being 
largely responsible for meeting an aerobic cell's ATP requirements (Berg et ai, 2007; Garrett et 
ai, 2010). 
The mitochondria plays a critical role in cell survival, mass production of an aerobic cells 
ATP supply, but also by influencing apoptosis, cell cycle, and metabolism (Naik and Dixit, 2011 ; 
Tschopp, 2011). Oxidation of glucose, pyruvate and NADH result in reactive oxygen species 
(ROS) as a byproduct, though normally the deleterious effects are removed by antioxidants (Naik 
and Dixit, 2011). However, several chronic inflammatoiy diseases also are characterized by 
excessive ROS production (Naik and Dixit, 2011). ROS perform essential roles in immune 
responses to pathogens, including death through the production of NADPH oxidases during the 
respiratory burst in activated macrophages and neufrophils (Bulua et ai, 2011). TNF-induced 
mitochondrial ROS have been implicated in cell death through inhibition of MAPK phosphatases 
(Bulua et ai, 2011). ROS activation of the inflammasome has been questioned as a distinct role 
for ROS in up-regulation of mRNA for inflammatory cytokines such as TNF (Bulua et ai, 
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2011). To avoid cellular damage ROS-generating mitochondria are constantly removed by 
mitophagy, a form of autophagy or cell death (Tschopp, 2011). 
The citric acid cycle is considered a catabolic process due to the oxidation of acetate side 
chains to CO2 and providing electrons for the electron transport of ATP and production. The 
citric acid cycle also fuels multiple biosynthetic processes by transamination of oxaloacetate, 
succinyl-CoA, a-ketoglutarate, and fumarate. A citric acid cycle intermediate, fumarie acid, is 
derived from fumarate. Downstream, fumarate can be trans-aminated to produce amino acids 
aspartate, asparagine, threonine, methionine, isoleucine, and lysine (Garrett et ai, 2010). Of 
considerable interest is that the intermediates in the citric acid cycle have been examined and 
tested for their immunomodulator capabilities, which could heighten or inhibit particular immune 
responses (Moharregh-Khiabani et ai, 2009). 
Fumarate has been examined for anti-inflammatoiy properties (Moharregh-Khiabani et 
ai, 2009; Gold et ai, 2012). In 1959 Dr. Schweckendiek, a German biochemist, hypothesized 
that a fumarate deficiency in the citric acid cycle was the cause of psoriasis (Asadullah et al., 
1997; Mrowietz and Asadullah, 2005; Yazdi and Mrowietz, 2008; Moharregh-Khiabani et al. 
2009). Over time he developed a mixture of fimiaric acid esters that successfully treated patient 
psoriasis symptoms, although free fumarie acid was associated with negative gastrointestinal 
effects (Asadullah et al., 1997; Mrowietz and Asadullah, 2005; Yazdi and Mrowietz, 2008; 
Moharregh-Khiabani et al. 2009). In 1994, a defined mixture of fiunaric acid esters was 
commercialized under the name Fumaderm (Jong et al., 1998; Mrowietz and Asadullah, 2005; 
Yazdi and Mrowietz, 2008; Moharregh-Khiabani et al. 2009). Recently, the Food and Drug 
Administration (FDA) approved Tecfidera (clinical trial name BG-12) as a suitable oral 
treatment for patients suffering from inflammatory conditions, such as relapse-remitting multiple 
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sclerosis (RRMS) and psoriasis. Tecfidera has been shown to possess anti-inflammatory and 
neuroprotective properties (FDA, 2013). Fumaderm and Tecfidera have a common main 
component known as dimethyl fiunarate that has been shown to be cell penetrant and hydrolyzed 
by intracellular esterases to its active metabolite monomethyl ñmiarate (MMF) (Moharregh-
Khiabani et al. 2009). 
RAW 264.7 cells, mouse monocyte cell line, has been utilized in prior studies for 
consistently demonstrating their ability to synthesize and release a host of markers of 
inflammation and have proven to be a valuable research tool for studying pathological and 
physiological inflammation in disease (Tweedie et al, 2009). A clustering of ligand interactions 
based on cytokine production originates from the existence of a limited set of interaction agents 
that provide the ability to integrate specific signaling pathways to yield unique output responses 
(Natarajan et al., 2006). RAW 264.7 cells have been shown to have a heterologous stably 
fransfected TNF-a-CAT fusion gene, which can be sfrongly induced by LPS at the 
franscriptional level. LPS has been suggested to function through the Raf/Ras signaling pathways 
that ultimately targets sequence elements present in the 3'-untranslated region (LFTR) of TNF-a 
mRNA (Raabe et al., 1998). RAW 264.7 cells secretes large amounts of TNF-a when LPS-
induced and has been extensively characterized. TNF-a mRNA can be detected in unstimulated 
RAW 264.7 cells then be strongly induced upon LPS-stimulation (Raabe et al., 1998). In the 
absence of LPS stimulation, RAW 264.7 cells produce small quantifiable amounts of TNF-a 
mRNA and protein. The increase of TNF-a mRNA and protein levels following LPS stimulation 
results primarily from franscriptional activation of the TNF-a gene (Raabe et ai, 1998). 
We utilized RAW 264.7 cells to generate a rapid and reproducible model of inflammation 
to evaluate dimethyl fumarate (DMF) and its active metabolite monomethyl fumarate (MMF) 
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anti-inflammatory action, cell viability and reactive oxygen species production. Dimethyl 
fumarate (DMF) and its active metabolite monomethyl fumarate (MMF) have been studied 
extensively for their anti-inflammatory and neuroprotective properties in various cell types (Jong 
et al., 1998; Mrowietz and Asadullah, 2005; Yazdi and Mrowietz, 2008; Moharregh-Khiabani et 
al. 2009; Gold et al., 2012). Our results indicate lOfiM DMF suppresses endotoxin-stimulated 
soluble TNF-a wiüi no effect on cell viability or ROS generation. 
5 
Methods and Materials 
Cell Culture 
The Abelson murine leukemia virus transformed macrophage TIB-71™ (RAW 264.7) 
was purchased from American Type Culture Collection (ATCC®, Manassas, VA). RAW 264.7 
cells were cultitfed in sterile 100mm petri dishes and 24-well cell culture dishes (VWR 
International, LLC , Radnor, PA) in Rosewell Park Memorial Institute 1640, RPMI, (containing 
GlutaMAX™, biotin (0.2mg/L), vitamin B12 (0.005mg/L), PABA (Img/L), high concentrations 
of vitamins (3mg/L choline chloride, 0.25mg/L D-calcium pantothenate, Img/L folic acid, 
Img/L niacinamide, Img/L pyridoxine hydrochloride, 0.2mg/L riboflavin, Img/L thiamine 
hydrochloride, and 35mg/L i-inostitol), and glutathione (Img/L), Invitrogen™/Life 
Technologies; Carlsbad, CA). RPMI media was supplemented with 5% fetal bovine serum (V/V) 
and 1% penicillin/streptomycin (10,000 units/mL penicillin/10,000 ng/mL streptomycin). The 
cells were incubated at 37°C in a humidified atmosphere of 5% CO2, 95% air. The cell cultures 
were passaged at 70% confluence, and plated for experiments 48 to 72 hours. 
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Fumarate Treatment 
RAW 264.7 cells were cultured in 24-well plates with RPM for 24 hours at 37°C in a 
humidified atmosphere of 5% CO2, 95% air. And then treated with either monomethyl fumarate 
(MMF) or dimethyl ñimarate (DMF) (Aldrich, St. Louis, MO) at concentrations of ImM, 3mM, 
and 5mM. Monomethyl fumarate samples were diluted in 7.4 pH phosphate buffered saline 
(PBS) (Invitrogen™/Life Technologies, CA). Dimethyl fumarate samples were diluted in 
dimethyl sulfoxide (DMSO) (Sigma, St/ Louis, MO). Following treatments, the plates were 
placed on a shaker at 200rpm for 5 minutes at room temperature then incubated for 2 hours or 24 
hours at 37°C in a humidified atmosphere of 5% CO2, 95% air. The supernatant was collected 
after incubation and stored at -20°C before analysis. TNF-a was quantified using a commercially 
available Enzyme Linked Immunoabsorbant Assay (Mouse TNF-a ELISA MAX™ Deluxe kit 
(BioLegend®; San Diego, CA)). 
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Endotoxin and Fumarate Treatment 
RAW 264.7 cells were cultured in 24-well plates with RPMI for 24 hours at 37°C in a 
humidified atmosphere of 5% CO2, 95% air. And then treated with or without endotoxin 
(l^g/mL) and either monomethyl fumarate (MMF) or dimethyl fumarate (DMF) (Aldrich, St. 
Louis, MO) at concentrations of 10|iM and 15nM. Monomethyl fumarate samples were diluted 
in 7.4 pH phosphate buffered saline (PBS) (Invitrogen™/Life Technologies, CA). Dimethyl 
fumarate samples were diluted in dimethyl sulfoxide (DMSO) (Sigma, St/ Louis, MO). The 
endotoxins utilized were Gram-negative lipopolysaccharide (LPS) and Gram-positive 
lipoteichoic acid (LTA) (Invitrogen™/Life Technologies, CA) at a concentration of l|.ig/mL. 
Following treatments, the plates were placed on a shaker at 200rpm for 5 minutes at room 
temperature then incubated for 2 hours or 24 hours at 37°C in a humidified atmosphere of 5% 
CO2, 95% air. The supernatant was collected after incubation and stored at -20°C before 
analysis. TNF-a was quantified using a commercially available Enzyme Linked 
Immunoabsorbant Assay (Mouse TNF-a ELISA MAX™ Deluxe kit (BioLegend®; San Diego, 
CA)). 
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TNF-a ELISA 
RAW 264.7 cell superaatants were thawed and then assayed for soluble TNF-a by 
ELISA. All reagents were used at room temperature. 
ELISA assays were carried out according to the manufactiu"er's instructions. Briefly, a 
NUNC flat-bottomed 96-well plate was prepared the day before performing the ELISA. The 5X 
Coating Buffer was diluted with deionized water to prepare a IX Coating Buffer solution. The 
IX Coating Buffer was then used to dilute the pre-titrated Capture Antibody in a 1:200 dilution. 
The diluted Capture Antibody was then placed into each well at a volume of 100|xL. The plate 
was then sealed and incubated overnight at 4°C. 
The following day a IX Assay Diluent was prepared. The plate was washed four times 
with 300jiL of Wash Buffer (PBS+0.05% Tween-20) per well. After the final addition, the plate 
was sealed, placed on a plate shaker and incubated at room temperature for 1 hour at 200rpm. 
Standards were prepared by serially diluting the 500pg/mL concentration according to 
manufacturer's instructions and assayed in triplicates at each concentration. To establish accurate 
cytokine levels, the supernatant of cells treated vwth LPS or LT A were diluted 1:10 for the 
exposure period of 2 hours, diluted 1:100 for the exposure period of 24 hours with IX Assay 
Diluent and then assayed for soluble TNF-a by ELISA. The plate was washed four times and the 
standards and samples we added. The plate was then sealed, placed on a plate shaker and 
incubated at room temperature for 2 hours at 200rpm. 
The biotinylated detection antibody was used at 1:200 final dilution. After incubation, 
each well was washed four times and the detection antibody was added. The plate was then 
sealed, placed on a plate shaker and incubated at room temperature for 1 hour at 200rpm. 
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After incubation, the plate was washed four times. For signal detection, Avidin-HRP 
(final dilution of 1:1000) was added and incubated at room temperature for 30 minutes at 
200rpm then washed five times. The 3', 3', 5', 5' tetramethylbenzadine substrate (TMB) was 
added and the plate was covered. To stop the reaction, lOOjiL of Stop Solution (2N H2SO4) was 
added to the wells and the resulting substrate colorimetric absorbance was determined at 450nm 
with a Spectra MAX 250 microplate reader (Molecular Devices, Sunnyvale, CA). The resulting 
data was stored using the SoftMax Pro 3.0 Software (Molecular Devices, Sunnyvale, CA). The 
results were then analyzed using GraphPad Prism version 5 (GraphPad Software, Inc., La Jolla, 
CA). 
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Cell Viability 
RAW 264.7 cells were cultured in 24-well plates with RPMI for 24 hours at 37°C as 
described above. After incubation the cells were treated with either MMF or DMF over the 
concentration range of Inm to lOOnM. Following treatment, the plates were placed on the shaker 
for 5 minutes at room temperature then incubated for 2 hours or 24 hours at 37°C in a humidified 
atmosphere of 5% CO2, 95% air. 
RAW 264.7 cell viability was assessed with the fluorescent viability dye, calcein-AM 
(Invitrogen™/Life Technologies, CA) as described (Blake, 2004). Briefly, after treatment the 
cell monolayers were washed with ImL PBS and then incubated with Ifig/mL calcein-AM in 
OptiMEM (Invitrogen™/Life Technologies, CA) containing penicillin/streptomycin (10,000 
imits/mL penicillin/10,000 ^g/mL streptomycin) for 20 minutes at 37°C in a humidified 
atmosphere of 5% CO2, 95% air. The monolayers were then washed once with ImL PBS and 
retained cellular fluorescence determined using a fluorescent plate reader (CytoFluor II, 
Perspective Biosystems, MA) with excitation at 485nm and emission at 530nm. The resulting 
data were exported and analyzed using GraphPad Prism version 5 (GraphPad Software, Inc., La 
Jolla, CA). 
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Reactive Oxygen Species Production 
RAW 264.7 cells were cultured in 24-well plates with RPMI for 24 hours at 37°C in a 
humidified atmosphere of 5% CO2, 95% air. Reactive oxygen production was stimulated 0.003% 
hydrogen peroxide (H2O2), with or without lug/mL LPS, and either MMF or DMF at 
concentrations of lO^M and 15nM. Following treatments, the plates were placed on a rotary 
shaker for 5 minutes then incubated for 2 hours at 37°C in a humidified atmosphere of 5% CO2, 
95% air. 
RAW 264.7 cell reactive oxygen species production was assessed with the fluorescent 
oxidative stress indicator, 6-chloromethyl 2',7'dichlorodihydrofluorescein diacetate (CM-
H2DCFDA; Invitrogen). Briefly, treated plates were washed with ImL PBS for 1 minute and 
then incubated with l^M CM-H2DCFDA in PBS for 20 minutes at 37°C in a humidified 
atmosphere of 5% CO2, 95% air. The monolayers were rinsed and the retained cellular 
fluorescence was quantified with a fluorescent plate reader (CytoFluor II, Perspective 
Biosystems, MA) with excitation at 485nm and emission at 530nm. The resulting data were 
exported and analyzed using GraphPad Prism version 5 (GraphPad Software, Inc., La Jolla, CA). 
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Results 
TNF-a release from RA W264.7 cells 
The effects of fumarie acid derivative monomethyl fumarate, MMF, or dimethyl 
fumarate, DMF, on the murine RAW 264.7 cells were examined at concentrations of ImM, 3mM 
and 5mM (Fig. 1). Cells exposed to MMF for 2 hours, resulted in a decrease in released, soluble 
TNF-a, though the decrease was not statistically significant (Fig. lA; P>0.05). One millimolar 
MMF, 3mM MMF and 5mM MMF decreased TNF-a by 26% (7.5±1.8pg/mL), 24% 
(7.7±2.2pg/mL) and 6% (9.5±0.35pg/mL) compared to the untreated control cells 
(10±1.0pg/mL). as shown in Figure IB, cells exposed to MMF for a longer period of 24 hours 
resulted in either a decrease or increase in soluble TNF-a that were not statistically significant 
when compared to control (P> 0.05). Three millimolar MMF resulted in a decrease in soluble 
TNF-a released by 23% (42±18pg/mL) compared to the untreated control cells (55±16pg/mL). 
However, ImM MMF and 5mM MMF increased soluble TNF-a by 90% (103±30pg/mL) and 
138% (130±54pg/mL) compared to the untreated control cells. Taken together, these results 
indicate no statistically significant effects of MMF on basal, soluble TNF-a. 
We next examined the ability of DMF to inhibit soluble TNF-a release. Cells were 
exposed to DMF for 2 hours and the soluble TNF-a response measured was not determined to be 
statistically significant when compared to the control cells (Fig. IC; P>0.05). Five millimolar 
DMF resulted in a decrease in soluble TNF-a by 53% (5.1±4.4pg/mL) compared to the untreated 
control cells (ll±4.8pg/mL). However, ImM DMF and 3mM DMF increased soluble TNF-a by 
127% (25±8.5pg/mL) and 5% (12±6.0pg/mL) compared to the corresponding untreated control 
cells. As shown in Figure ID, cells exposed to DMF for 24 hours resulted in a decrease in 
soluble TNF-a release that was not statistically significant (P>0.05). At 24 hours, ImM DMF, 
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3mM DMF and 5mM DMF decreased soluble TNF-a by 32% (26±9.3pg/mL), 66% 
(13±6.9pg/mL) and 77% (8.9±3.7pg/mL) compared to the untreated control cells (38±17pg/mL). 
MMF and DMF resulted in both increases and decreases in soluble TNF-a release by 
RAW 264.7 cells, although the results were not statistically different from control, soluble TNF-
a levels. Based on these results, MMF and DMF do not significantly impact basal soluble TNF-a 
release. 
We next examined the effects of MMF and DMF on LPS and LTA endotoxin-stimulated 
TNF-a release at concentrations of either lO^M or 15|xM in combination with the Gram-negative 
endotoxin LPS (l^g/mL; Fig. 2A and 2B) or the Gram-positive endotoxin LTA (l^g/mL; Fig. 
2C and 2D). To establish accurate cytokine levels, the supernatant of cells treated with LPS or 
LTA were diluted 1:10 for the exposure period of 2 hours, diluted 1:100 for the exposure period 
of 24 hours and then assayed for soluble TNF-a by ELISA. Cells exposed to LPS for 2 hours 
significantly stimulated a 13-fold increase in soluble TNF-a (188±37pg/mL; ***P<0.001) 
compared to the untreated control cells (15±2.5pg/ml). The addition of lOjxM MMF or 15 ^M 
MMF to the LPS-stimulated cells reduced the LPS-soluble TNF-a by 32% (127±6.7pg/mL) and 
30% (132±2.0pg/mL) compared to the LPS-stimulated cells. However, this reduction in soluble 
TNF-a was not statistically significant (P>0.05). Cells treated with LPS for 2 hours in the 
presence of lO^iM DMF or 15 ^M DMF reduced the LPS-stimulated soluble TNF-a by 69% 
(59±4.4pg/mL; **P<0.01) and 44% (105±17pg/mL; P>0.05) compared to the LPS-stimulated 
cells (Fig. 2A). LPS-stimulated cells with the addition of lO^M DMF significantly reduced the 
soluble TNF-a released compared to LPS-stimulated cells. 
As shown in Figure 2B, cells exposed to LPS for the longer period of 24 hours 
significantly stimulated a 4-fold increase (73%) in soluble TNF-a (226±12pg/mL; ***P<0.001) 
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compared to the untreated control cells (62±llpg/mL) due to the longer exposure time. The 
addition of lOfiM MMF or 15jiM MMF to the LPS-stimulated cells reduced the LPS-soluble 
TNF-a by 7% (210±27pg/mL) and 1% (224±30pg/mL) compared to the LPS-stimulated cells. 
However, this reduction in soluble TNF-a was not statistically significant (P>0.05). Cells treated 
with LPS for 24 hours in the presence of lO^tM DMF or 15 fiM DMF significantly reduced the 
LPS-stimulated soluble TNF-a by 63% (83±16pg/mL; •*P<0.01) and 45% (123±17pg/mL; 
*P<0.05) compared to the LPS-stimulated cells. 
These results (Fig. 2A and 2B) show that, at both exposure periods 10|iM DMF 
significantly reduced soluble TNF-a compared to LPS-stimulated cells and LPS-stimulated cells 
significantly increased soluble TNF-a compared to untreated control cells. At both exposure 
periods, DMF was more effective than MMF in reducing the release of LPS-stimulated soluble 
TNF-a from RAW 264.7 cells. Taken together (Fig. 2A and 2B), our results show that lOfiM 
DMF was the more effective concentration for reducing the LPS-stimulated soluble TNF-a at the 
2 and 24 hour exposures. Based on these results, it can be concluded that lOuM DMF can be a 
potential therapy for inappropriate TNF-a release. This can be attributed to the chemical 
structural difference of DMF having two methyl groups allowing it to cross the cell membrane 
and to be cleaved by intemal esterases into the active metabohte monomethyl fumarate. 
We next examined the effects of the Gram-positive bacterial endotoxin, LTA, on soluble 
TNF-a release from RAW 264.7 cells (Fig. 2C and 2D). Cells exposed to LTA for two hours 
significantly stimulated a 2.5-fold (144%) increase in soluble TNF-a (35±3.8pg/mL; *P<0.05) 
compared to the untreated control cells (14±3.8pg/mL). The addition of lOuM MMF or 15^M 
MMF increased LTA-soluble TNF-a by 8% (38±4.1pg/mL) and 8% (38±1.9pg/mL) compared to 
the LTA-stimulated cells (P>0.05). Cells treated with LTA for 2 hours in the presence of lO^M 
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DMF reduced the LTA-stimulated soluble TNF-a by 60% (14±1.7pg/mL; **P<0.01) compared 
to the LTA-stimulated cells. The presence of lOjiM DMF in combination with LTA reduced the 
soluble TNF-a to the basal level of the untreated control cells (14pg/mL). Fifteen micromolar 
DMF reduced the LTA-stimulated soluble TNF-a by 12% (31±4.8pg/mL; P>0.05) compared to 
the LTA-stimulated cells (Fig. 2C). LTA-stimulated cells with the addition of lOfiM DMF 
significantly reduced the soluble TNF-a released compared to LPS-stimulated cells. The 
structural differences between MMF and DMF allow DMF to enter the cell and break down to 
the active metabolite MMF. MMF does not enter the cell to the extent that DMF does. 
As shown in Figure 2B, cells exposed to LPS for the longer period of 24 hours 
significantly reduced soluble TNF-a by 57% (28±6.7pg/mL; ***P<0.001) compared to the 
untreated control cells (65±6.0pg/mL). However, if you take into account the dilution of the LTA 
supematant the soluble TNF-a increased by 43-fold (2800±670pg/mL) compared to the untreated 
control. The addition of lOfiM MMF to LTA-stimulated cells increased soluble TNF-a by 24% 
(3500±240pg/mL; P<0.05) compared to the LTA-stimulated cells (2800±670pg/niL). However, 
the addition of 15nM MMF to LTA-stimulated cells reduced soluble TNF-a by 7% 
(2600±120pg/mL; P<0.05) compared to the LTA-stimulated cells. Cells treated with LTA for 24 
hours in the presence of lOfiM DMF or 15nM DMF increased soluble TNF-a by 15% 
(3200±430pg/mL; P<0.05) and 33% (3700±470pg/mL; P<0.05). 
Figure 2C and 2D show that lO^M DMF significantly reduced LTA-stimulated soluble 
TNF-a at an exposure period of 2 hours compared to the control, LTA-stimulated cells. LTA-
stimulated cells significantly increased soluble TNF-a compared to the untreated control cells at 
both exposure periods. Taken together (Fig. 2C and 2D), our results show that lO^M DMF was 
the most effective concentration reducing LTA-stimulated soluble TNF-a at 2 hours of exposure. 
Based on these results, it can be concluded that MMF at both exposure periods and DMF at 24 
hours of exposure were not effective in reducing LTA-stimulated soluble TNF-a. 
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Figure 1. TNF-a release in response to MMF or DMF. RAW 264.7 cells were incubated with ImM MMF, 3mM 
MMF, 5mM MMF, ImM DMF, 3inM DMF, or 5mM DMF. A and C. After 2 hours the supernatant was collected 
to access the concentration of soluble TNF-a released. The results shown are means ± SEM for three 24-well plates, 
each assayed in triplicate. B and D. After 24 hours the supernatant was collected to access the concentration of 
soluble TNF-a released by ELISA. The results shown are means ± SEM for three 24-well plates, each assayed in 
triplicate (P> 0.05), 
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Figure 2. TNF-a release after endotoxin exposure and either MMF treatment or DMF treatment. RAW 264.7 cells 
were incubated with lOuM MMF, IS^M MMF, lOuM DMF or IS^M DMF, in the presence of Ijig/mL LPS or 
LTA A and C. After 2 hours the supernatant was collected to access the concentration of soluble TNF-a released. 
The results shown are means ± SEM for three 24-well plates, each assayed in triplicate. B and D. After 24 hours the 
supematant was collected to access the concentration of soluble TNF-a released by ELISA. The results shown are 
means ± SEM for two 24-well plates, each assayed in triplicate. Statistical comparisons via GraphPad PRISM show 
significance: A. »**P< 0.001 Control vs. LPS; **P<0,01 LPS vs. LPS + 10|iM DMF. B. ***P< 0.001 Control vs. 
LPS; **P<0.01 LPS vs. LPS + 10^M DMF; and •P<0.05 LPS vs. LPS + 15nM DMF. C. *P<0.05 Control vs. LTA; 
**P<0.01 LTA vs. LTS + 10^M DMF D. »**P<0.001 Control vs. LTA. 
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RAW264.7 cell viability with MMF and DMF 
We next examined the effects of MMF and DMF on cell viability. Mrowietz and 
Asadullah (2006) showed that DMF induced apoptosis in immune cells, so we generated a 
concentration response curve, with final MMF and DMF concentrations ranging fi-om InM to 
lOO^M (Fig. 3, 4, 5 and 6). A two hour exposure with MMF of increasing concentrations fi"om 
InM to 750nM resulted in an insignificant increase in cell viability when compared to the 
imtreated control cells (7,060±529 F.U.; Fig. 3A). MMF at 250nM increased viability by 30% 
(9,172±1243 F.U.) compared to the untreated control cells. One nanomolar MMF, 25nM MMF, 
75nM MMF and 500nM MMF increased viability 24% (8,776±511 F.U.), 26% (8,907±912 
F.U.), 23% (8,713±1027 F.U.) and 25% (8,819±694 F.U.), respectively. The lowest increases in 
viability were observed at 150nM MMF and 750nM MMF at 11% (7,831±1039 F.U.) and 7% 
(7,569±796 F.U.) compared to the untreated control cells. However, the increases in viability 
indicate no statistically significant effects of nanomolar MMF on basal cell viability (P>0.05). 
A two hour exposure with MMF (l|iM to lOO^iM) had a variable response on cell 
viability, though not a statistically significant effect. MMF at luM, lO^tM and ISjiM reduced 
viability by 3% (9,295±501 F.U.), 7% (8,867±803 F.U.) and 7% (8,916±346 F.U.), respectively, 
compared to the untreated control cells (9,538±569 F.U.). However, 50nM MMF, 75nM MMF 
and lOOjiM MMF increased viability by % (10,323±522 F.U.), 8% (10,318±615 F.U.) and 3% 
(9,864±836 F.U.), respectively, compared to the untreated control cells. In contrast, 25nM MMF 
decreased viability by 0.3% compared to the untreated control cells (Fig. 3B; P>0.05). 
A two hour concentration response curve for DMF demonstrated a variable cell viability 
response, although no statistically significant effect was observed. A reduction in viability was 
observed at 25nM DMF, 75nM DMF and 150nM DMF by 20% (4,220±437 F.U.), 28% 
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(3,799±353 F.U.) and 38% (3,272±262 F.U.), respectively, compared to the untreated control 
cells (5,272±529 F.U.; P>0.05; Fig. 4A). DMF at InM, 250nM and 750nM reduced viability by 
4% (5,070±825 F.U.), 12% (4,628±470 F.U.) and 14% (4,545±396 F.U.), respectively, compared 
to the untreated control cells (P>0.05). However, DMF at 500nM increased viability by 3% 
(5,416±1035 F.U.) compared to the imtreated control cells (P>0.05). 
As seen in Figure 4B, a two hour exposure period with DMF (1 jiM to lOOuM) resulted in 
a reduction in cell viability throughout the concentration response curve though the decrease was 
not statistically significant. Ten micromolar DMF and 50^M DMF reduced viability by 9% 
(6,081±285 F.U.) and 7% (6,222±723 F.U.) compared to the untreated control cells (6,671±517 
F.U.; P>0.05). MMF at IS^M, 25nM and 75fiM reduced viability by 13% (5,826±348 F.U.), 
13% (5,807±308 F.U.) and 19% (5,423±547 F.U.), respectively, compared to the untreated 
control cells (P>0.05). The highest reduction in viability was observed at l^M and lOOjxM 
reducing viability 26% (4,946±578 F.U.) and 23% (5,155±474 F.U.) compared to the untreated 
control cells (P>0.05). 
We next examined the effects of MMF and DMF on cell viability with an exposure 
period of 24 hours. A twenty-four hour exposure with MMF (InM to 750nM) resulted in a 
variable response in cell viability, although not statistically significant (Fig. 5A). Twenty-five 
nanomolar MMF, 150nM MMF and 500nM MMF increased viability by 3% (13,801±355 F.U.), 
7% (14,400±777 F.U.) and 5% (14,090±1101 F.U.), respectively, compared to the untreated 
control cells (13,460±935 F.U.; P>0.05). MMF at 75nM, 250nM and 750nM increased viabiHty 
by 12% (15,041±935 F.U.), 13% (15,212±765 F.U.) and 11% (14,987±805 F.U.), respectively, 
compared to the untreated control cells (P>0.05). However, a reduction in viability was observed 
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at InM MMF by 19% (10,898±759 F.U.) compared to the untreated control cells which was not 
statistically significant (P>0.05). 
As shown in Figure 5B, a 24 hour exposure to MMF (IjiM to lOO^iM) resulted in 
insignificant reductions in cell viability. Ten micromolar MMF, 25nM MMF and SOfiM MMF 
reduced viability by 6% (18,282±779 F.U.), 8% (17,785±817 F.U.) and 6% (18,182±757 F.U.), 
respectively, compared to the imtreated control cells (19,358±2244 F.U.; P>0.05). MMF at l^M, 
15^M and lOO^M reduced viability by 16% (16,263±972 F.U), 19% (15,725±787 F.U.) and 
11% (17,281±539 F.U.), respectively, compared to the untreated control cells (P>0.05). In 
contrast, 75jiM MMF increased viability by 0.3% compared to the untreated control cells 
(P>0.05). 
Although Figures 3, 4 and 5 suggest increases and decreases in cell viability with respect 
to MMF and DMF at 2 hours of exposure and MMF at 24 hours of exposure, the concentration 
response curves show no significant increase or decrease in cell viability. The insignificant 
increases and decreases show that at the exposures times for MMF and DMF the concentrations 
are not toxic to the cell due to fiimarate being an intermediate of the citric acid cycle. The 
filmane acid derivatives can be utilized in the cells citric acid cycle and the CO2 oxidized can 
enter the electron transport chain. However, once the CO2 can lead to toxic or non-toxic effects 
depending upon the results from the electron transport chain. 
Exposure to DMF (InM to 750nM) for 24 hours resulted in a reduction in cell viability 
that was statistically significant (Fig. 6A). One nanomolar DMF, 25nM DMF, 500nM DMF and 
750nM DMF reduced viability by 34% (8,303±840 F.U.; »P<0.05), 35% (8,196±1148 F.U.; 
*P<0.05), 35% (8,210±640 F.U.; •P<0.05) and 35% (8,135±823 F.U.; *P<0.05), respectively, 
compared to the untreated control cells (12,614±472 F.U.). The highest reduction in cell viability 
was observed in the response curve at 150nM and 250nM by 43% (7,166±584 F.U.; **P<0.01) 
and 40% (7,594±658 F.U.; •*P<0.01) compared to the untreated control cells. However, 75 nM 
DMF reduced viability by 15% (10,664±1406 F.U.; P>0.05) compared to the untreated control 
cells. 
As seen in Figure 6B, DMF (IjiM to lOOjiM) resulted in an insignificant increase and 
decrease in cell viability (P>0.05). Fifty micromolar DMF and 75^iM DMF reduced viability by 
7% (11,726±940 F.U.) and 5% (12,039±1299 F.U.) compared to the untreated control cells 
(12,652±2407 F.U.). DMF at IjiM, lOuM and lOOjiM reduced viability by 16% (10,650±1223 
F.U.), 19% (10,244±832 F.U.) and 26% (9,405±1078 F.U.) compared to the untreated control 
cells. In contrast, 15nM DMF and 25^M DMF increased viability by 6% (13,372±1322 F.U.) 
and 4% (13,181±900 F.U.) compared to the untreated control cells. 
These results (Fig. 6A and 6B) show that DMF acts in an opposite manner at 24 hours of 
exposure than at an exposure period of 2 hours. DMF in the concentration response curve range 
(InM to 750nM) resulted in statistically significant reduction in cell viability at InM, 25nM, 
150nM, 250nM, 500nM and 750nM compared to the untreated control cells. Based on the 
results, exposure to nanomolar DMF is detrimental to the viability of RAW 264.7 cells. 
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Figure 3. A MMF concentration response curve (InM to lOOjiM). RAW 264.7 cell monolayers were incubated for 2 
hours in the presence or absence of MMF A. After treatment with MMF (InM to 750nM), cell viability was 
determined with calcein-AM fluorescence. B. After treatment with MMF (luM to lOOuM), cell viability was 
determined with calcein-AM fluorescence. The resuks presented are means ± SEM for three 24-well plates, each 
assayed in triplicate (P>0.05). 
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Figure 4. A DMF concentration response curve (InM to lOOfiM), RAW 264.7 cell monolayers were incubated for 2 
hours in the presence or absence of DMF A. After treatment with DMF (InM to 750nM), cell viability was 
determined with calcein-AM fluorescence. B. After treatment with DMF (luM to lOOuM), cell viability was 
determined with calcein-AM fluorescence. The results presented are means ± SEM for three 24-well plates, each 
assayed in triplicate (P>0.05). 
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Figure 5. A MMF concentration response curve (InM to lOOuM). RAW 264.7 cell monolayers were incubated for 
24 hours in the presence or absence of MMF A. After treatment with MMF (InM to 750nM), cell viability was 
determined with calcein-AM fluorescence. B. After treatment with MMF (IjiM to lOOuM), cell viability was 
determined with calcein-AM fluorescence. The results presented are means ± SEM for three 24-well plates, each 
assayed in triplicate (P>0,05). 
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Figure 6. A DMF concentration response curve (InM to lOOjiM). RAW 264.7 cell monolayers were incubated for 
24 hours in the presence or absence of DMF. A. After treatment with DMF (InM to 750nM), cell viability was 
determined with calcein-AM fluorescence. B. After treatment with DMF (l^M to lOOuM), cell viability was 
determined with calcein-AM fluorescence. Statistical comparisons via GraphPad PRISM show significance: A. 
•P<0.05 Control vs. InM DMF, *P<0.05 Control vs. 25nM DMF, **P<0.01 Control vs. 150nM DMF, »*P<0.01 
Control vs. 250nM DMF, •P<0.05 Control vs. 500nM DMF and *P<0.05 Control vs. 750nM DMF. B. P>0.05 
25 
Reactive Oxygen Species Production with MMF and DMF 
We next examined the effects MMF and DMF had on the production of reactive oxygen 
species (ROS). Albrecht et al. (2012) showed that DMF at low concentrations protected neuronal 
cells from oxidative stress. Gold et al. (2012) showed fumarie acid esters have the potential to 
induce the Nrf-2 pathways thereby increasing the pathways ability to mediate neuroprotective 
effects. So we used MMF and DMF at concentrations of lOjiM and 15jiM alone and in 
combination with hydrogen peroxide (H2O2; 0.003%) and Gram-negati ve endotoxin LPS 
(l^g/mL) for an exposure period of two hours (Fig. 7). 
We first stimulated RAW 264.7 with LPS and the addition of lOjiM MMF, ISjxM MMF, 
IOjaM DMF or 15fiM DMF, which results in an insignificant variation in ROS production 
compared to the untreated control cells (646±3.0 F.U.; P>0.05). Due to the insignificant 
reduction in ROS production, we added a known ROS, hydrogen peroxide (3%), to the cells to 
produce ROS. 
To examine if ROS were produced by cells, the cells were stimulated with hydrogen 
peroxide as a means of a positive control that resulted in an insignificant increase (P>0.05). We 
exposed cells to H2O2 and combinations of H2O2 with MMF or DMF. Cells were exposed to 
H2O2, H2O2 with LPS and lO^M MMF, H2O2 with LPS and 15^lM MMF, H2O2 with LPS and 
lOjiM DMF and H2O2 with LPS and IS^M DMF that resulted in an insignificant variation in 
ROS production compared to the unfreated confrol cells. The addition of the hydrogen peroxide 
resulted in insignificant ROS production. To see if MMF and DMF themselves had an effect on 
ROS production, we freated with MMF and DMF alone to account for their effects. 
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To examine the effect that MMF and DMF have alone on ROS production, we exposed 
cells to lO^iM MMF, 15|iM MMF, lOjiM DMF and 15|iM DMF that resulted in a marginal 
though insignificant increase in ROS production (P>0.05). 
These data (Fig. 7) suggest that MMF and DMF alone or in combination with LPS and 
H2O2 did not significantly increase or decrease ROS production. Future experimentation will be 
required to determine if MMF and DMF can inhibit ROS production. 
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Figure 7. Reactive oxygen species (ROS) production with MMF and DMF with hydrogen peroxide (H2O2) and LPS 
(lUg/mL). RAW 264.7 cells were incubated with lOjiM MMF, ISjiM MMF, lOjiM DMF or IS^M DMF, in the 
presence or absence of 0.003% H2O2 and lug/mL LPS for 2 hours. ROS production was determined by CM-
H2DCFDA fluorescence and the results presented are means ± SEM for three 24-well plates, each assayed in 
quadruple (P>0.05). 
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Discussion 
The host's defense mechanisms are important on its survivability. Classically activated 
macrophages are products of the cell-mediated immune response signals, interferon-y (IFNy) and 
tumor-necrosis factor (TNF). Classically activated macrophages are vital to the host defense, 
although their actions are tightly regulated due to tissue damage cytokines and mediators can 
produce (Mosser and Edwards, 2008). If this process becomes deregulated it can lead to several 
autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease and multiple 
sclerosis. The detrimental effects of deregulated cytokine release and ways to inhibit their release 
have become increasingly researched. Dimethyl fumarate has been utilized since 1959 to treat 
psoriasis in Germany and in 2013 to treat relapse-remitting multiple sclerosis (FDA, 2013). 
The differences in immune response also correlate to damage that may occur. We utilized 
exposure periods of 2 and 24 hours to emulate acute and chronic inflammation as describe in 
previous literature were fumarate was utilized as treatment. Furthermore, previous literature 
showed serum peak concentration of 20^lM for the active metabolite MMF, therefore we utilized 
concentrations at lO^iM and 15jiM to determine the effects MMF and DMF had on TNF-a 
secretion, cell viability, and ROS production (Gold et al., 2012). Although the titration range for 
treatment could be far larger, the range was limited due to previous literature stating DMF 
induced apoptosis in immune cells at high concentration up to lOOjiM (Mrowietz and Asadullah, 
2006). 
LPS has been shown to trigger the wide spread production of TNF-a by macrophages 
(Feghali and Wright, 1997). Treatment of macrophages or adherent mononuclear cells with LTA 
has been shown to induce TNF-a (Grunfeld et al, 1999). In the present study, we showed an 
increase in soluble TNF-a with cells stimulated with LPS or LTA compared to basal levels 
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(Figure 2). Previous literature states lOjiM DMF attenuated TNF-a production (Albrecht et al, 
2012), which was seen in cells stimulated with LPS and LTA (Fig. 2A, 2B and 2C). DMF has 
been shown to alter the cytokine levels in cell culture (Ockenfels et al, 1998). We have shown 
that IS^M has also reduced TNF-a from cells stimulated with LPS or LTA (Fig. 2A, 2B and 
2C). 
The active metabohte, monomethyl fiimarate, used in peripheral blood mononuclear cells 
(PBMC) and monocytes induced TNF-a in the presence or absence of LPS-stimulated cells for 2 
and 24 hours (Asadullah et al, 1997). MMF addition to LPS-stimulated or LTA-stimulated cells 
reduced and increased soluble TNF-a, although MMF did not reduce to the same level as DMF 
(Figure 2). This could be due to DMF being more lipophilic than MMF, which allows DMF to 
enter the cell at a faster rate and in larger quantities compared to MMF (Yazdi and Mrowietz, 
2008). 
Previous literature showed that DMF induced apoptosis in monocyte derived dendritic 
cells and T cells (Mrowietz and Asadullah, 2006). The concenfration response curve showed 
significant reduction in cell viability in the nanomolar range of DMF for 24 hours of exposure 
(Figure 6). Out results are not consistent with those observed by Albrecht et al (2012) where 
lOOjiM DMF caused an increase in cell death by apoptosis. Moharregh-Khiabani et al (2009) 
and Gold et al (2012) observed DMF at higher concenfrations induced apoptosis in all cell 
types. A potential explanation for our results differing can be the incubation time or the cell 
normal microenvironment. Further experimentation would have to occur to determine if the 
results we obtain do not correlate with the literature. 
The survival of the cell is dependent upon the adaptability of responding to outside 
stimulus and applying mechanisms to combat the stimulus. Previous literature showed DMF has 
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potential for protecting cells from oxidative sfress (Albrecht et ai, 2012 and Gold et ai, 2012). 
Activated macrophages and neutrophils utilize ROS to perform essential roles in immune 
responses to pathogens, which include death through the production of NADPH oxidases during 
the respiratory burst (Bulua et ai, 2011). The deleterious effects which normally occur if left 
imtreated can be removed by antioxidants. Nrf-2 (nuclear factor (erythroid-derived-2)-like 2) 
pathway has been implicated as the neuroprotective mechanism utihzed by DMF and MMF 
(Scannevin et ai, 2012; Linker et ai, 2011; Wilms et ai, 2010). LPS, tumor-necrosis factor 
(TNF), and reactive oxygen species/reactive nifrogen sepecies all activate autophagy, and it is 
well known that LPS friggers ROS production (Yuan et ai, 2009). FAE induced an upregulation 
of the production of superoxide anion in monocytes (Moharregh-Khiabani et ai, 2009) DMF 
interferes with the cellular redox system by modulating intracellular thiols and thereby increasing 
the level of reduced glutathione. DMF decreased the LPS induced production of TNF-a and 
increased the cellular glutathione (Gold et ai, 2011). Our results had insignificant variation 
comparing the treated cells with the untreated control cells. RAW 264.7 cells become 
macrophages when placed onto the freated surface of a well plate, which could potentially 
explain why the freatments did not affect the cells. A more potent positive confrol, a higher 
percentage of hydrogen peroxide, peroxyl radical or hydroxyl radical, may provide valuable 
insight on if MMF and DMF can protect the cells. With a new positive confrol, we could make a 
better determination on if MMF and DMF have neuroprotective effects. From this data we could 
explore the pathway utilized to protect tìie cell or verify previous literature stating the Nrf-2 
pathway. 
The reduction of soluble TNF-a from LPS-stimulated or LTA-stimulated cells, cell 
viability, and reactive oxygen species production could be attributed to autophagy. The cells can 
undergo autophagy if they are presented with signals or outside stimulus. Autophagy is active at 
basal levels in most cell types where it is postulated to play a housekeeping role in maintaining 
the integrity of the cell. However, autophagy is strongly induced by starvation and is a key 
component of the adaptive response of cells and organisms to undergo nutrient deprivation that 
promotes survival until nutrients are available again. Autophagy is generally thought of as a 
survival mechanism, although its deregulation has been linked to non-apoptotic cell death (Glick 
et al, 2011). 
In summary, we have found that lOjiM DMF significantly reduced soluble TNF-a release 
from murine monocyte cell line RAW 264.7. We found nanomolar DMF significantly reduced 
cell viability. Reactive oxygen species were not produced or inhibited to a detectable level in all 
treatments. The significant reduction in soluble TNF-a, cell viability was maintained, and 
reactive oxygen species were not produced at lOfiM DMF would indicate that this concentration 
has the potential to treat the detrimental effects of deregulated cytokine release. 
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Conclusions 
In the present study, we examined two methylated derivatives of fumarate, DMF and 
MMF. We determined that lO^M DMF significantly inhibited soluble TNF-a released from 
murine monocyte cell line RAW 264.7 cells stimulated with LPS with no effect on cell viability 
or ROS generation. MMF and DMF had minimal effects on cell viability. Reactive oxygen 
species generation was unaltered by DMF treatment. The significant reduction in soluble TNF-
a, maintained cell viability and lack of reactive oxygen species indicate DMF at lOfiM is anti­
inflammatory with minimal monocyte cytotoxicity. 
Despite, clear clinical utility, the cellular mechanism of DMF action remains unknown. 
Future studies focusing on monocyte cellular metabolism, pro-inflammatoiy gene transcription, 
translation, processing and release might provide valuable insights. For example, DMF may 
impact the post-translational processing and membrane presentation of TNF-a. By utilizing flow 
cytometry in conjunction with TNF-a selective antisera the plasma membrane presentation could 
be monitored. Establishing the intracellular target of DMF might also provide the groundwork 
for fiiture small molecule anti-inflammatory molecules. 
Furthermore, changing the cell line to a neuroblastoma N-type could provide valuable 
insight to the mechanisms which MMF and DMF have on neuronal cells. The concentrations of 
fiimarate can be titrated in a wider fashion to determine the most suitable concentration for future 
studies. Various autoimmune disorders affect the nervous system in some manner, therefore 
finding suitable treatments for these diseases have the potential to find cures in time. 
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